Revolution Medicines (RVMD) News Today → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free RVMD Stock Alerts $36.26 -0.17 (-0.47%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSG Americas Securities LLC Trims Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)marketbeat.com - April 20 at 4:12 AMRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Mirae Asset Global Investments Co. Ltd.marketbeat.com - April 19 at 4:39 AMValidea Detailed Fundamental Analysis - RVMDnasdaq.com - April 17 at 2:28 PMRevolution Medicines (RVMD) Price Target Increased by 5.15% to 41.65msn.com - April 17 at 2:28 PMRevolution Medicines executive sells over $619k in company stockinvesting.com - April 15 at 12:41 AMRevolution Medicines director sells shares worth $79,735investing.com - April 14 at 9:40 AMSushil Patel Sells 2,155 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stockamericanbankingnews.com - April 14 at 7:22 AMMark A. Goldsmith Sells 7,500 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stockamericanbankingnews.com - April 14 at 6:08 AMRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $45.00 at Oppenheimeramericanbankingnews.com - April 14 at 5:14 AMInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells 2,155 Shares of Stockinsidertrades.com - April 13 at 7:10 AMInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 7,500 Shares of Stockmarketbeat.com - April 12 at 9:27 PMRevolution Medicines, Inc. (NASDAQ:RVMD) Short Interest Down 26.8% in Marchmarketbeat.com - April 12 at 2:50 PMBuy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer Therapiesmarkets.businessinsider.com - April 12 at 2:35 PMRevolution Medicines (NASDAQ:RVMD) PT Raised to $45.00 at Oppenheimermarketbeat.com - April 12 at 8:27 AMRevolution Medicines reports progress in RAS cancer therapyuk.investing.com - April 11 at 7:19 PMRevolution Medicines (NASDAQ:RVMD) Reaches New 52-Week High at $37.62marketbeat.com - April 11 at 3:20 PMWhat's Going On With Revolution Medicines Stock?msn.com - April 10 at 2:34 PMRevolution Medicines (NASDAQ:RVMD) Upgraded to "Strong-Buy" at Raymond Jamesmarketbeat.com - April 10 at 9:08 AMRevolution Medicines reports breakthrough in RAS-mutant cancer treatmentuk.investing.com - April 10 at 1:37 AMRevolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteinsglobenewswire.com - April 9 at 3:34 PMRevolution Medicines’ Robust Cancer Drug Pipeline Justifies Buy Ratingmarkets.businessinsider.com - April 8 at 2:23 PMRevolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteinsglobenewswire.com - April 8 at 11:36 AMNeedham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)marketbeat.com - April 8 at 8:20 AMRevolution Medicines to Participate in Upcoming Investor Conferencesglobenewswire.com - April 4 at 4:05 PMRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Rating of "Buy" from Brokeragesmarketbeat.com - April 2 at 4:22 AMInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells 1,500 Shares of Stockinsidertrades.com - March 29 at 8:56 AMVanguard Group Inc. Has $266.94 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)marketbeat.com - March 29 at 4:18 AMRevolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 1,500 Sharesmarketbeat.com - March 28 at 7:55 PMRevolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024globenewswire.com - March 28 at 4:05 PMRevolution Medicines executive sells over $67,000 in stockinvesting.com - March 22 at 10:45 PMRevolution Medicines general counsel sells $39,542 in stockinvesting.com - March 22 at 10:45 PMRevolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 1,252 Sharesinsidertrades.com - March 21 at 10:33 AMRevolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells $39,538.16 in Stockmarketbeat.com - March 20 at 7:54 PM49,600 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Wedmont Private Capitalmarketbeat.com - March 17 at 7:55 AMRVMD Apr 2024 36.000 callfinance.yahoo.com - March 16 at 3:40 PMRVMD Apr 2024 33.000 putfinance.yahoo.com - March 16 at 10:40 AMRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Wellington Management Group LLPmarketbeat.com - March 15 at 6:22 AMRVMD Sep 2024 21.000 putca.finance.yahoo.com - March 15 at 3:46 AMRVMD Mar 2024 33.000 putfinance.yahoo.com - March 15 at 3:46 AMRVMD Mar 2024 36.000 callfinance.yahoo.com - March 15 at 3:46 AMRVMD Apr 2024 21.000 putca.finance.yahoo.com - March 14 at 10:46 PMRVMD Apr 2024 21.000 callca.finance.yahoo.com - March 14 at 10:46 PMRevolution Medicines Inc. (US76155X1000.SG)finance.yahoo.com - March 14 at 5:46 PMBuy Rating on Revolution Medicines Amid Promising RMC-6236 Trials for Multiple Cancer Treatmentsmarkets.businessinsider.com - March 11 at 10:43 AMRevolution Medicines (NASDAQ:RVMD) Earns Overweight Rating from Analysts at Piper Sandlermarketbeat.com - March 11 at 8:16 AMMorgan Stanley Maintains Equal-Weight Rating for Revolution Medicines: Here's What You Need To Knowmarkets.businessinsider.com - March 8 at 1:10 PMRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by Brokeragesmarketbeat.com - March 8 at 3:26 AMRVMD Apr 2024 31.000 putfinance.yahoo.com - March 7 at 11:00 AMSeven Eight Capital LP Has $1.23 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)marketbeat.com - March 7 at 8:41 AMQube Research & Technologies Ltd Invests $6.05 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)marketbeat.com - March 6 at 6:09 AM Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet. See how you can invest alongside him RVMD Media Mentions By Week RVMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVMD News Sentiment▼0.910.46▲Average Medical News Sentiment RVMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVMD Articles This Week▼43▲RVMD Articles Average Week Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PCVX News EXEL News CRSP News HALO News KRYS News IMVT News MRTX News IBRX News IOVA News SWTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVMD) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
